153 related articles for article (PubMed ID: 21074436)
21. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
22. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
Li YW; Hill G; Wong H; Kelly N; Ward K; Pierdomenico M; Ren S; Gilligan P; Grossman S; Trainor G; Taub R; McElroy J; Zazcek R
J Pharmacol Exp Ther; 2003 Apr; 305(1):86-96. PubMed ID: 12649356
[TBL] [Abstract][Full Text] [Related]
23. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
Ye Y; Liao Q; Wei J; Gao Q
Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
Zhang G; Huang N; Li YW; Qi X; Marshall AP; Yan XX; Hill G; Rominger C; Prakash SR; Bakthavatchalam R; Rominger DH; Gilligan PJ; Zaczek R
J Pharmacol Exp Ther; 2003 Apr; 305(1):57-69. PubMed ID: 12649353
[TBL] [Abstract][Full Text] [Related]
25. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
Chorvat RJ; Bakthavatchalam R; Beck JP; Gilligan PJ; Wilde RG; Cocuzza AJ; Hobbs FW; Cheeseman RS; Curry M; Rescinito JP; Krenitsky P; Chidester D; Yarem JA; Klaczkiewicz JD; Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Zaczek R; Fitzgerald LW; Huang SM; Shen HL; Wong YN; Chien BM; Arvanitis A
J Med Chem; 1999 Mar; 42(5):833-48. PubMed ID: 10072681
[TBL] [Abstract][Full Text] [Related]
27. Expression of type 1 corticotropin-releasing factor receptor in the guinea pig enteric nervous system.
Liu S; Gao X; Gao N; Wang X; Fang X; Hu HZ; Wang GD; Xia Y; Wood JD
J Comp Neurol; 2005 Jan; 481(3):284-98. PubMed ID: 15593376
[TBL] [Abstract][Full Text] [Related]
28. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides.
Behan DP; De Souza EB; Lowry PJ; Potter E; Sawchenko P; Vale WW
Front Neuroendocrinol; 1995 Oct; 16(4):362-82. PubMed ID: 8557170
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
[TBL] [Abstract][Full Text] [Related]
30. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Hartz RA; Ahuja VT; Zhuo X; Mattson RJ; Denhart DJ; Deskus JA; Vrudhula VM; Pan S; Ditta JL; Shu YZ; Grace JE; Lentz KA; Lelas S; Li YW; Molski TF; Krishnananthan S; Wong H; Qian-Cutrone J; Schartman R; Denton R; Lodge NJ; Zaczek R; Macor JE; Bronson JJ
J Med Chem; 2009 Dec; 52(23):7653-68. PubMed ID: 19954247
[TBL] [Abstract][Full Text] [Related]
31. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
Oshida Y; Ikeda Y; Chaki S; Okuyama S
Life Sci; 2004 Feb; 74(15):1911-24. PubMed ID: 14761672
[TBL] [Abstract][Full Text] [Related]
32. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
33. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
[TBL] [Abstract][Full Text] [Related]
34. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
Yamada Y; Mizutani K; Mizusawa Y; Hantani Y; Tanaka M; Tanaka Y; Tomimoto M; Sugawara M; Imai N; Yamada H; Okajima N; Haruta J
J Med Chem; 2004 Feb; 47(5):1075-8. PubMed ID: 14971886
[TBL] [Abstract][Full Text] [Related]
35. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
36. Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency.
Turcu AF; Spencer-Segal JL; Farber RH; Luo R; Grigoriadis DE; Ramm CA; Madrigal D; Muth T; O'Brien CF; Auchus RJ
J Clin Endocrinol Metab; 2016 Mar; 101(3):1174-80. PubMed ID: 26751191
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
[TBL] [Abstract][Full Text] [Related]
38. Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
Di Fabio R; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Sabbatini FM; Andreotti D; Spada S; Marchioro C; Worby A; St-Denis Y
J Med Chem; 2008 Nov; 51(22):7273-86. PubMed ID: 18975927
[TBL] [Abstract][Full Text] [Related]
39. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
Gordon JC; Edwards P; Elmore CS; Lazor LA; Paschetto K; Bostwick R; Sylvester M; Mauger R; Scott C; Aharony D
Eur J Pharmacol; 2010 Dec; 649(1-3):59-63. PubMed ID: 20854803
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
